IOVS Papers in Press. Published on February 20, 2014 as Manuscript iovs.14-13916

Circulating omega-3 fatty acids and neovascular age-related macular degeneration

Bénédicte MJ. Merle,[1] Pascale Benlian,[2,3] Nathalie Puche,[1] Ana Bassols,[4] Cécile Delcourt,[5,6] Eric H. Souied, [1] for the Nutritional AMD Treatment 2 Study Group*

[1] Ophthalmology Department, Hôpital Intercommunal de Créteil, University Paris Est Créteil, Créteil, France.

[2] CHRU Lille, Biochemistry and Molecular Biology Institute, Molecular Medicine of Metabolic Diseases (U4M), F-59037, Lille, France.

[3] Lille2 University, School of Medicine, Department of Biochemistry and Molecular Biology, F-59045 Lille, France.

[4] Laboratoire Bausch+Lomb, Montpellier, France

[5] INSERM, Centre INSERM U897-Epidemiologie-Biostatistique, F-33000 Bordeaux, France.

[6] Univ. Bordeaux, ISPED, F-33000 Bordeaux, France.

Word count: 3 520

Financial Support/Grant: This study was sponsored by Laboratoire Bausch & Lomb, Clinical Research, 416, rue Samuel Morse, CS 99535, 34961 Montpellier, Cedex 2, France. Benedicte Merle received a grant from Fédération des aveubles et handicaps visuels de France and from Fondation Nestlé France.

Running head: Circulating Omega 3 fatty acids and AMD.

Corresponding author/reprint request:

Bénédicte Merle benedicte.merle@u-bordeaux.fr Service d'ophtalmologie CHIC Créteil, 40 avenue de Verdun 94000 Créteil, France.

ABSTRACT

Purpose: To assess the associations of serum, red-blood cell membranes (RBCM) and dietary long-chain n-3 polyunsaturated fatty acids (LC-PUFAs) with neovascular age-related macular degeneration (AMD).

Methods: We included 290 patients of the Nutritional AMD Treatment 2 Study (NAT2) with neovascular AMD in one eye and early AMD lesions in the other eye and 144 normal vision controls without AMD. Dietary intake of seafood was estimated by food frequency questionnaire. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) composition in serum and RBCM were determined by gas chromatography from 12h-fasting blood samples and was expressed as percentages of total fatty acids profile. Logistic regressions estimated associations of neovascular AMD with dietary intake of seafood and circulating n-3 LC-PUFAs.

Results: Dietary oily fish and seafood intake were significantly lower in AMD patients than in controls. After adjustment for all potential confounders (age, gender, *CFH Y402H, ARMS2 A69S, and ApoE4* polymorphisms, plasma triglycerides, hypertension, hypercholesterolemia and family history of AMD), serum EPA was significantly associated with a lower risk for neovascular AMD (OR=0.41 (0.22-0.77); p=0.005). Analysis of RBCM revealed that EPA and EPA+DHA were significantly associated with a lower risk for neovascular AMD (OR=0.25 (0.13-0.47); p<0.0001 and OR=0.52 (0.29-0.94); p=0.03, respectively).

Conclusions: RBCM EPA and EPA+DHA, as long term biomarkers of n-3 dietary PUFA status, were strongly associated with neovascular AMD and may represent an objective marker identifying subjects at high risk for neovascular AMD, whom may most benefit from nutritional interventions.

53 **Keywords**: age-related macular degeneration, omega 3 fatty acids, epidemiology,
54 case-control study.

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in industrialized countries.[1] It comprises two late forms both associated with severe visual impairment (neovascular and atrophic AMD), generally preceded by early, asymptomatic, retinal abnormalities (drusen, pigmentary abnormalities). Treatments for neovascular AMD are available since a few years. Although, they stabilize vision, they are not curative, supporting the need for a targeted prevention towards high-risk asymptomatic subjects, identified by relevant biomarkers.

AMD is a multifactorial disease, involving genetic and environmental factors (in particular smoking and nutrition).[1] Omega3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have important structural and protective functions in the retina.[2] DHA reaches its highest concentration in the membranes of photoreceptors and is important in photoreceptor differentiation and survival, as well as in retinal function.[2] The anti-inflammatory properties of EPA and DHA[2, 3] are of particular interest in AMD, since inflammation appears to play a pivotal role in this condition.[4] Moreover, n-3 LC-PUFAs may increase the retinal density of macular pigment, which filters blue light and has local antioxidant and anti-inflammatory activities.[5] Finally, derivatives of dietary n-3 LC-PUFAs, exhibit antiangiogenic properties in the retina.[6]

In 2008, a meta-analysis[7] of nine epidemiological studies[8-16] showed a significantly reduced risk for AMD in subjects with high dietary intake of n-3 PUFAs and fish, the main food source of n-3 PUFAs. Since then, ten additional studies have shown similar and consistent results.[17-26]

Dietary assessment methods rely on the subjects' memory and perceptions and face the difficulties of the extreme day-to-day variability of human diet, the hidden nature of many fats used for dressing and cooking, the bias in reporting due to social

80 standards and nutritional recommendations, and the estimation of the nutritional
81 content of foods. Because of the multiple difficulties of dietary assessment,
82 circulating biomarkers may represent a more objective alternative for the assessment
83 of nutritional status.[27] A better assessment of n-3 nutritional status could help identify
84 high-risk subjects, whom may most benefit from nutritional intervention. Such
85 biomarkers might also be used to follow the efficacy of nutritional interventions in
86 restoring adequate nutritional status.
87 Over the last 20 years, a number of biomarkers have been developed to assess the
88 nutritional status in fatty acids according to different source tissues. Because of very
89 limited capacity of endogenous synthesis, the body status of n-3 LC-PUFA mainly
90 reflects dietary intake of these essential fatty acids. The shortest-term biomarkers of
91 n-3 LC-PUFA body status are serum or plasma measurements, reflecting dietary
92 intakes of the past few hours for triglycerides or of the past few days for cholesterol
93 ester and phospholipid fatty acids carried within circulating lipoproteins. Red blood
94 cell membranes (RBCM) and platelets are of particular interest since they reflect
95 longer-term overall dietary intake of n-3 LC-PUFA, incorporated within membrane
96 phospholipids of bone-marrow derived cell-lines during the past few months.[28]
97 Because n-3 fatty acids may undergo variable interconversion after intestinal
98 absorption, the omega-3 index (i.e. RBCM EPA+DHA) appears as an interesting
99 long-term integrator of n-3 LC-PUFA body status.[29]
100 Circulating n-3 PUFAs have been evaluated in numerous studies, showing good
101 correlation with dietary intake, and sensitivity to changes in dietary supplementation
102 studies.[27] They have been widely used in association studies of n-3 PUFAs with a
103 variety of health outcomes (cardiovascular diseases, obesity and diabetes, chronic
104 inflammatory or neuro-psychiatric disorders, cancers, etc.).[30-34] However, with regard

105 to AMD, while many studies have reported associations with dietary intakes of n-3
106 PUFAs, very few data are available on associations of AMD with circulating
107 biomarkers of n-3 PUFA status. Recently, we have shown that high plasma n-3 LC-
108 PUFAs were significantly associated with a decreased risk for late AMD in elderly
109 subjects from South of France.[35] This study used a single plasma measurement
110 which represented a crude estimate of body fatty acid status. Measurement of n-3
111 PUFAs in RBCM may represent a better biomarker for longer term status, with a half-
112 life of 120 days.[28]
113 In the present study, we report the associations of dietary intake of seafood, serum
114 and RBCM n-3 LC-PUFAs with neovascular AMD in a French case-control study.

METHODS

Study population

Cases: The 290 cases of neovascular AMD were included from Nutritional AMD Treatment 2 Study (NAT2) baseline examination.[36] NAT2 study is a randomized, placebo-controlled, double blind, parallel, comparative study. Patients were enrolled from December 2003 to October 2005 in a single center at the Department of Ophthalmology, Hôpital Intercommunal de Creteil, France. The study was reviewed and approved by the relevant institutional review board (CPP, Paris-Ile de France 5, Paris, France).

Eligible patients were affected by neovascular AMD in one eye and early AMD (any drusen or reticular pseudodrusen with or without pigmentary changes) in the other eye. Neovascular AMD was defined on the basis of fundus color pictures and fluorescein angiography examination. Inclusion criteria were as follows: (1) age 55 years or older and younger than 85 years, (2) visual acuity better than +0.4 logarithm of minimum angle of resolution units in the study period[36]. The main exclusion criteria were: (1) CNV in both eyes or no CNV in either eye, (2) wide central subfoveal atrophy of the study eye and (3) progressive ocular diseases (severe glaucoma or other severe retinopathy).[36]

Eye examination included best-corrected visual acuity, slit-lamp examination, fundus photography and fluorescein angiography (Topcon501A, Tokyo, Japan). The study was registered on the International Standard Randomized Controlled Trial Number Register and was allocated registration number ISRCTN98246501.

Controls: Controls were enrolled through local-newspapers calls for collaboration. A total of 144 men and women, aged 55 years or more, with normal visual acuity, no history of ocular diseases and normal fundus examination and fundus photography

were recruited and examined at the Department of Ophthalmology of Creteil between 2002 and 2008. Controls were from the same geographical area as the AMD cases. Written informed consent was obtained for all participants (cases and controls), as required by the French bioethical legislation and local ethic committee (CPP Henri Mondor). This study followed the tenets of the Declaration of Helsinki.

Biological measurements of fatty acids

Overnight fasting blood samples were delivered to a single clinical chemistry laboratory (Hôpital Saint Antoine, APHP, Paris) within five hours and processed immediately as described.[36] For cases, blood samples collected at baseline examination (before any supplementation), were used for the present study. For controls, blood samples were obtained at the time of eye examination.

Fatty acid composition in serum and RBCM was determined by gas chromatography after they were transmethylated by diazomethane following a modified Dole's procedure.[37] Results for EPA and DHA content were expressed as a percentage of the total fatty acid profile in serum and RBCM and were available for all participants (n=434).

Other Biomarkers

Biological samples were collected in the same conditions and at time of fatty acid measurements. They included serum lipids and lipoproteins and genetic polymorphisms validated as genetic markers of exudative AMD.

Serum total, HDL- and LDL-cholesterol and triglycerides, were measured by enzymatic colorimetric and electrophoretic methods as previously described.[38] Genomic DNA was extracted from 10 mL blood leukocytes as previously described in

AMD patients[39] and using the Illustra® kit according to the manufacturer's protocol (GE Healthcare) in controls. Genotyping of *CFH* rs1061170, *ARM2/HTRA1* rs10490924, and *Apolipoprotein E2, 3, 4* alleles were performed by quantitative polymerase chain reaction allelic discrimination using reagents and conditions from Custom Taqman Single-Nucleotide Polymorphism Genotyping Assays (Applera, Corp, France), using ABI 7900HT (Applied Biosystems). Quality control of genotyping by Sanger sequencing and bioinformatics analysis were performed as described.[39]

Dietary data

Dietary data were collected using a validated food frequency questionnaire (FFQ) that recorded the usual food intakes for the last year[16, 40, 41]. The interview was conducted by trained technicians, by telephone and lasted 45 to 60 minutes. The FFQ consists of 165 items and portions were estimated using a validated set of photographs. The set of photographs was given to the patient before the telephone interview. It was arranged by food type and meal pattern. In the analysis, the intakes were expressed in daily consumption in grams. The food composition table was REGAL[42] (Ciqual) expanded with carotenoid and fatty acid contents from the SU.VI.MAX table.[43] Total dietary intake of seafood is the sum of oily fish, white fish and other seafood and total dietary intake of fish is the sum of oily fish and white fish. Dietary data were available for 423 participants (97.4 %).

Covariates

Socio-demographic factors and medical history were collected through face-to-face, standardized interviews at the same time as eye examination. They included age, gender, BMI [weight (kg)/height^2 (m^2)], smoking status (never smoker or ever

190 smoker), self-reported history of hypercholesterolemia, hypertension, diabetes and
191 family history of AMD, circulating biomarkers: serum total, HDL- and LDL-cholesterol
192 and triglycerides, and genetic biomarkers: *CFH* rs1061170, *ARM2/HTRA1*
193 rs10490924, and *Apolipoprotein E2,* and *E4* alleles. All covariates were available for
194 all participants (n=434).
195
196 **Statistical analyses**
197 Comparison between neovascular AMD patients and controls were performed using
198 Pearson Chi^2 for gender, Student's *t* test for age and logistic regression adjusted for
199 age and gender for other variables.
200 Associations of circulating n-3 PUFAs and fish intake with socio-demographic factors,
201 medical history, dietary intake of seafood and genetic polymorphisms were
202 performed using Kruskal-Wallis ANOVA and Wilcoxon test.
203 Associations of neovascular AMD with dietary intake of seafood and circulating n-3
204 PUFAs were estimated using logistic regression. Potentials confounders retained in
205 the final multivariate model were factors significantly associated with neovascular
206 AMD or n-3 PUFAs in our study (hypercholesterolemia, hypertension, family history
207 of AMD, plasma triglycerides and *CFH*, *ARMS2* and *ApoE4* polymorphisms; $p<0.05$).
208 Dietary intake of seafood and circulating n-3 PUFAs variables were used as tertiles
209 of distribution, the first tertile being the reference.
210 We also analyzed potential gene-environment interactions and potential age- and
211 gender-circulating n-3 PUFAs interactions. Interactions were independently
212 introduced in the fully adjusted model and retained if they were significant ($p<0.05$).
213 For all analyses, differences were considered significant at $p<0.05$. All statistical
214 analyses were performed using SAS version 9.3 (SAS Institute, Inc Cary, NY, USA).

RESULTS

As shown in Table 1, neovascular AMD patients were older than controls ($p<0.0001$), but were not different regarding gender, smoking status and BMI (Table 1). After adjustment for age and gender, neovascular AMD patients declared more frequently a family history of AMD ($p=0.004$), hypercholesterolemia ($p=0.004$), or hypertension ($p=0.001$) both latter conditions being under stable corrective therapy. Frequency of self-declared diabetes did not differ between neovascular AMD patients and controls. Regarding genetic polymorphisms, *CFH Y402H* ($p<0.0001$), *ARMS2 A69S* ($p<0.0001$) and *ApoE4* ($p=0.03$) polymorphisms were significantly associated with neovascular AMD. Neovascular AMD patients had lower plasma triglycerides than controls ($p=0.0009$), while they had similar plasma total, HDL- and LDL-cholesterol (Table 1). Neovascular AMD patients had lower serum EPA ($p=0.03$), RBCM EPA ($p<0.001$), RBCM DHA ($p=0.03$) and omega-3 index (RBCM EPA+DHA, $p=0.001$) than controls, while they had serum DHA and EPA+DHA similar to controls after adjustment for age and gender (Table 1). Neovascular AMD patients had lower dietary intake of oily fish ($p=0.02$) and total seafood ($p=0.03$) than controls, but were not different regarding dietary intake of total fish, white fish and other seafood (Table 1).

Table 2 presents the associations of fish intake and circulating n-3 fatty acids with socio-demographic factors, medical history and genetic polymorphisms. Younger participants had a higher dietary intake of oily fish than older participants ($p=0.0003$). Men had a higher dietary intake of total and oily fish (respectively $p=0.002$ and $p=0.005$). Participants who declared hypertension had lower dietary intake of oily fish ($p=0.003$). Participants with at least one allele E4 for *ApoE* polymorphism had higher dietary intake of total fish and oily fish (respectively $p=0.03$ and $p=0.03$). Other socio-

demographic factors, lifestyle and AMD-related genetic polymorphisms were not associated with dietary intake of fish or seafood. Remarkably, none of the circulating n-3 LC-PUFAs appeared influenced by any of the socio-demographic, medical or genetic risk factors for AMD analyzed herein.

As shown in Table 3, serum EPA, DHA and EPA+DHA were significantly associated with all items of dietary intake of seafood (total fish, oily fish, white fish, other seafood and total seafood). Subjects in the 3rd tertile, for all seafood items, had higher serum EPA, DHA and EPA+DHA. The same trend was observed with RBCM EPA, DHA and EPA+DHA and reached statistical significance for all items of dietary intake of seafood except for RBCM DHA and white fish (p=0.08). Of note, the median omega-3 index (i.e. RBCM EPA+DHA) was constantly >4, in subjects from the 3rd tertile, for all seafood items.

As shown in Table 4, after adjustment for age and gender, dietary intake of total seafood and of total fish were inversely associated with neovascular AMD (respectively p=0.05 and p=0.04). After adjustment for all potential confounders (age, gender, *CFH Y402H, ARMS2 A69S, and ApoE4* polymorphisms, plasma triglycerides, hypertension, hypercholesterolemia and family history of AMD), these associations were no longer statistically significant. With regard to dietary intake of oily fish, white fish or other seafood, associations were in the same direction but did not reach statistical significance.

Associations of neovascular AMD with circulating n-3 PUFAs are shown in Table 5. After adjustment for age and gender, serum EPA was significantly associated with a lower risk for neovascular AMD (OR=0.59, p=0.04), while serum DHA and EPA+DHA were not significantly associated with neovascular AMD. This association remained significant after adjustment for all potential confounders (p=0.005).

With regard to RBCM n-3 PUFAs, after adjustment for age and gender, EPA and EPA+DHA were strongly associated with a lower risk for neovascular AMD (OR=0.33, $p<0.0001$ and OR=0.44, $p=0.002$, respectively) and after adjustment for all potential confounders, these associations remained significant (OR=0.25, $p<0.0001$ and OR=0.52, $p=0.03$, respectively). As in serum, DHA in RBCM was not significantly associated with neovascular AMD.

There was no detectable interaction between dietary intake of seafood or circulating n-3 PUFAs with *CFH*, *ARMS2* or *ApoE* genetic polymorphisms, age or gender.

DISCUSSION

In the present study, a high RBCM EPA+DHA index (omega-3 index) was significantly associated with a 48 % reduction of the odds of neovascular AMD. The associations of neovascular AMD with EPA status appeared also particularly strong (OR=0.25, p<0.0001 for RBCM EPA and OR=0.41 p=0.005 for serum EPA).

In the present study, the results of seafood consumption are consistent with previous dietary studies. Although AMD patients had significantly lower oily fish and seafood intake than controls, associations did not reach statistical significance after adjustment for all potential confounders. Among published case-control studies reporting associations between fish consumption and AMD, one found a significant association[18] whereas 3 studies, including the AREDS study, showed no significant association.[11-13] Moreover, in 2008, a meta-analysis estimated that the risk for late AMD was reduced by 38 % in participants with high dietary intakes of n-3 LC-PUFAs.[7] Since then, 4 large prospective[20, 21, 24, 26] and 4 large cross-sectional[18, 19, 23, 25] dietary studies published consistent and similar results.

The present results for serum EPA+DHA are consistent with the only published study on plasma n-3 LC-PUFAs in AMD, from the population-based Alienor Study.[35] This study showed a 33 % decreased risk for neovascular AMD in subjects with high plasma n-3 LC-PUFAs, however not reaching statistical significance (OR=0.67, p=0.08).[35] Interestingly, AMD risk was found here, in a new and independent sample of the French population, in the same range (OR=0.74, p=0.35) for serum EPA+DHA. In Alienor study, plasma EPA was not associated with neovascular AMD (p=0.51), while plasma DHA was borderline with neovascular AMD (p=0.06). In the present study, we found a significant association with serum EPA (p=0.005) but not with serum DHA (p=0.81).

298 To our knowledge, the present study is the first case-control study reporting
299 associations of RBCM n-3 long-chain fatty acids with neovascular AMD. We show
300 significant and strong associations of neovascular AMD with RBCM EPA and RBCM
301 EPA+DHA. As expected, association with AMD was stronger for RBCM than serum
302 measurements, because EPA or DHA measured in RBCM are more stable and
303 longer-term biomarkers of body LC-PUFAs homeostasis and less influenced by
304 lifestyle or other endogenous factors than EPA+DHA in serum or plasma.[28]
305 In the present study, associations of neovascular AMD with circulating EPA (in serum
306 and RBCM) were markedly stronger than with circulating DHA. This could reflect
307 differences in endogenous metabolism of n-3 LC-PUFA, which could be more readily
308 visible through circulating EPA than through circulating DHA. For example, there is
309 high inter-individual variability with different tissue-specific rates of EPA/DHA inter-
310 conversion, depending on age, gender, nutritional or metabolic conditions.[29]
311 Moreover, although DHA is quantitatively more abundant than EPA in serum or cell-
312 membranes, changes in serum and RBCM EPA are more pronounced than serum or
313 RBCM DHA, with changes in dietary intakes of EPA+DHA, even in subjects taking n-
314 3 LC-PUFA oral supplements exclusively enriched in DHA.[29] Alternately, the
315 protective role of EPA is supported by oxidative metabolism by cyclooxygenases and
316 lipoxygenases to produce eicosanoids with vasoregulatory and anti-inflammatory
317 properties in the retina.[2] EPA is also the precursor of docosapentaenoic acid (DPA),
318 which is known to be the potential precursor of n-3 very long chain PUFAs (VLC-
319 PUFAs) including 24:5 n-3 fatty acid, the most abundant VLC-PUFA present in the
320 retina.[44] A recent study has observed a decreased of some n-3 VLC-PUFAs (notably
321 24:5 n-3) in early and intermediate AMD retinas as compared to age-matched
322 control.[44] Finally, two randomized, prospective, placebo-controlled, clinical trials have

323 tested the efficiency of oral n-3 LC-PUFAs supplementation on late AMD
324 development.[36, 45] First, the NAT2 study found no effect of a three-year oral
325 EPA+DHA (1:3, EPA:DHA (mg/mg ratio) from fish-oil) on progression from early AMD
326 to neovascular AMD, in the second eye of patients with unilateral neovascular AMD
327 at baseline.[36] Second, AREDS2 primary analyses showed that addition of
328 lutein+zeaxanthin, EPA+DHA (2:1, EPA:DHA (mg/mg ratio) from ethyl esters) or
329 both to the AREDS formulation did not further reduce the 5-year risk of progression
330 from early to late AMD (geographic or neovascular AMD).[45] Remarkably, in placebo
331 groups from both trials, incidence of late AMD at follow-up was lower than that
332 expected from observational studies, suggesting that trial-effects (e.g., healthy
333 lifestyle, unreported self-supplementation in LC-PUFA, etc.) might have reduced
334 statistical study power in both randomized trials. Therefore, these two recent clinical
335 trials, may not challenge more than one decade of observational studies in favor of a
336 protective effect of dietary n-3 PUFAs on AMD. The AREDS study recently published
337 that five years after the clinical trial end, the beneficial effects of the AREDS
338 formulation persisted for development of neovascular AMD, suggesting a potential
339 long-term effect of nutritional factors involved in AMD pathogenesis.[46] Moreover, in
340 the NAT2 study, the 3-year incidence of CNV was significantly reduced (HR 0.32; CI
341 95% 0.10-0.99; p=0.047) in patients achieving the highest RBCM EPA+DHA (omega-
342 3 index >8) over 3 years.[36] From these combined results, it seems to be relevant to
343 analyse n-3 RBCM EPA+DHA status in AMD. Biological status of n-3 PUFAs could
344 help identifying those subjects at risk for AMD, and RBCM n-3 PUFAs appears more
345 relevant as a biomarker of AMD.
346 Strength of our study was the combined use of biological data, mainly EPA+DHA
347 RBCM measurements with dietary assessment of n-3 PUFA status, in the same

348 groups of individuals affected or not with AMD. Indeed, from differences in well-
349 established risk factors (age, medical history, *CFH*, *ARMS2* and *APOE*
350 polymorphisms) found with a group of normal vision/normal fundus individuals, the
351 AMD group seemed as typical of a population of patients with exudative AMD.
352 Although apparently paradoxical, that triglycerides were found significantly lower in
353 AMD patients despite them being more numerous with dyslipidemia, may be
354 somewhat expected since the whole population had plasma triglycerides
355 concentrations within the normal range, including AMD patients regularly taking lipid-
356 lowering medications. Finally, the omega-3 index (EPA+DHA index) measured in
357 RBCM is a very good biomarker of n-3 PUFAs status in humans and recognized as a
358 risk factor in cardiovascular diseases.[47] In the future, it may prove useful in the
359 clinical setting, for the identification of AMD patients deficient in n-3 LC-PUFAs,
360 which may benefit the most from nutritional intervention.
361 Selection of controls is always a concern in case-control studies, selection bias being
362 difficult to avoid.[48] In the present study, controls were selected from the general
363 population, in the same geographical area as cases. They were not aware of the
364 specific objectives of the study, before the interview and blood sample. When we
365 compared cases and controls, they were not different for gender, smoking, body
366 mass index, diabetes and plasma cholesterol. However, cases were older than
367 controls. Also, hypercholesterolemia and hypertension were more frequent in cases,
368 which is partially consistent with previous studies.[49] Our two groups were also
369 comparable for dietary intakes. To limit the potential bias due to differences in age,
370 hypertension or hypercholesterolemia, we used multivariate modeling. However,
371 despite that we adjusted our analyses for these potential confounders, as well as

major AMD-related genes, we cannot exclude residual confounding as in all epidemiological studies.

Also, as our study focused on neovascular AMD cases only, our results can be generalized only to this type of AMD.

In conclusion, from the present report, elderly individuals with high RBCM level of EPA+DHA - a long-term marker of intracellular LC-PUFAs - have a strongly reduced risk for neovascular AMD. This suggests the RBCM EPA+DHA index to be considered as added to the list of clinically relevant biomarkers of AMD.

Acknowledgment:

Nat2 Study Group (alphabetic order):

Catherine Allaire[1], MD, Ana Bassols[1], MD, Khaldia Belabbas[2], PharmD, Dominique Brault[1], Yves Brouquet[1], Stéphanie Castagnet, PharmD[2], Antoine Crié[2], Isabelle Gaudino[2], Patricia Gawrilow[4], MD, Michèle Lablache-Combier[1], PhD, Nicolas Leveziel[3], MD, PhD, Nadja Mechai [1],PhD, MSc, Gilles Morineau, PharmD, PhD[2], Natasa Orlic-Pleyer[1], MD, Brigitte Paccou[3], Nicole Pumariega[4], Giuseppe Querques[3], Raphaële Siou-Mermet[1], MD, MS, Isabelle Turquois[2].

1. Laboratoires Bausch+Lomb, F-34961, Montpellier, France.
2. APHP - Hôpital Saint Antoine - Laboratoire de Biochimie B - F-75012 Paris, France.
3. Service d'Ophtalmologie - Hôpital Intercommunal de Créteil – Université Paris Est Créteil - 40, Avenue de Verdun - 94000 Créteil, France
4. Department of Ophthalmology, NYU School of Medicine, New York, NY, USA

The authors would like to thank all physicians, nurses and patients from Creteil university eye clinic; all biologists in particular Dr Claude Wolf for scientific advice and support, all laboratory technicians particularly Dominique Farabos, Myriam Mahe, Dominique Labaud for excellent technical assistance, from Biochimie B laboratory from Saint Antoine Hospital.

399 **REFERENCES**

400

401 1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular
402 degeneration. *Lancet* 2012;379:1728-1738.
403 2. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated
404 fatty acids in health and disease of the retina. *Prog Retin Eye Res* 2005;24:87-138.
405 3. Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival
406 signaling in stroke, retinal degenerations, and Alzheimer's disease. *J Lipid Res*
407 2009;50 Suppl:S400-405.
408 4. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The Role of
409 Inflammation in the Pathogenesis of Age-related Macular Degeneration. *Surv*
410 *Ophthalmol* 2006;51:137-152.
411 5. Delyfer MN, Buaud B, Korobelnik JF, et al. Association of macular pigment
412 density with plasma omega-3 fatty acids: the PIMAVOSA study. *Invest Ophthalmol*
413 *Vis Sci* 2012;53:1204-1210.
414 6. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of
415 omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. *Nat*
416 *Med* 2007;13:868-873.
417 7. Chong EW, Kreis AJ, Wong TY, Simpson JA, Guymer RH. Dietary omega-3
418 fatty acid and fish intake in the primary prevention of age-related macular
419 degeneration: a systematic review and meta-analysis. *Arch Ophthalmol*
420 2008;126:826-833.
421 8. Chua B, Flood V, Rochtchina E, Wang JJ, Smith W, Mitchell P. Dietary fatty
422 acids and the 5-year incidence of age-related maculopathy. *Arch Ophthalmol*
423 2006;124:981-986.
424 9. Cho E, Hung S, Willett WC, et al. Prospective study of dietary fat and the risk
425 of age-related macular degeneration. *Am J Clin Nutr* 2001;73:209-218.
426 10. Arnarsson A, Sverrisson T, Stefansson E, et al. Risk factors for five-year
427 incident age-related macular degeneration: the Reykjavik Eye Study. *Am J*
428 *Ophthalmol* 2006;142:419-428.
429 11. Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk for advanced
430 age-related macular degeneration. *Arch Ophthalmol* 2001;119:1191-1199.

12. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. *Arch Ophthalmol* 2006;124:995-1001.

13. SanGiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. *Arch Ophthalmol* 2007;125:671-679.

14. Mares-Perlman JA, Brady WE, Klein R, VandenLangenberg GM, Klein BE, Palta M. Dietary fat and age-related maculopathy. *Arch Ophthalmol* 1995;113:743-748.

15. Heuberger RA, Mares-Perlman JA, Klein R, Klein BE, Millen AE, Palta M. Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey. *Arch Ophthalmol* 2001;119:1833-1838.

16. Delcourt C, Carriere I, Cristol JP, Lacroux A, Gerber M. Dietary fat and the risk of age-related maculopathy: the POLANUT study. *Eur J Clin Nutr* 2007;61:1341-1344.

17. Robman L, Vu H, Hodge A, et al. Dietary lutein, zeaxanthin, and fats and the progression of age-related macular degeneration. *Can J Ophthalmol* 2007;42:720-726.

18. Augood C, Chakravarthy U, Young I, et al. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. *Am J Clin Nutr* 2008;88:398-406.

19. SanGiovanni JP, Chew EY, Agron E, et al. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. *Arch Ophthalmol* 2008;126:1274-1279.

20. Tan JS, Wang JJ, Flood V, Mitchell P. Dietary fatty acids and the 10-year incidence of age-related macular degeneration: the Blue Mountains Eye Study. *Arch Ophthalmol* 2009;127:656-665.

21. SanGiovanni JP, Agron E, Clemons TE, Chew EY. Omega-3 long-chain polyunsaturated fatty acid intake inversely associated with 12-year progression to advanced age-related macular degeneration. *Arch Ophthalmol* 2009;127:110-112.

22. Parekh N, Voland RP, Moeller SM, et al. Association between dietary fat intake and age-related macular degeneration in the Carotenoids in Age-Related Eye

464 Disease Study (CAREDS): an ancillary study of the Women's Health Initiative. *Arch*
465 *Ophthalmol* 2009;127:1483-1493.
466 23. Merle B, Delyfer MN, Korobelnik JF, et al. Dietary omega-3 fatty acids and the
467 risk for age-related maculopathy: the Alienor Study. *Invest Ophthalmol Vis Sci*
468 2011;52:6004-6011.
469 24. Christen WG, Schaumberg DA, Glynn RJ, Buring JE. Dietary omega-3 fatty
470 acid and fish intake and incident age-related macular degeneration in women. *Arch*
471 *Ophthalmol* 2011;129:921-929.
472 25. Swenor BK, Bressler S, Caulfield L, West SK. The impact of fish and shellfish
473 consumption on age-related macular degeneration. *Ophthalmology* 2010;117:2395-
474 2401.
475 26. Reynolds R, Rosner B, Seddon JM. Dietary Omega-3 Fatty Acids, Other Fat
476 Intake, Genetic Susceptibility, and Progression to Incident Geographic Atrophy.
477 *Ophthalmology* 2013.
478 27. Serra-Majem L, Nissensohn M, Overby NC, Fekete K. Dietary methods and
479 biomarkers of omega 3 fatty acids: a systematic review. *Br J Nutr* 2012;107 Suppl
480 2:S64-76.
481 28. Arab L. Biomarkers of fat and fatty acid intake. *J Nutr* 2003;133 Suppl 3:925S-
482 932S.
483 29. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose
484 response of n-3 fatty acids in humans. *Am J Clin Nutr* 2006;83:1467S-1476S.
485 30. Feart C, Peuchant E, Letenneur L, et al. Plasma eicosapentaenoic acid is
486 inversely associated with severity of depressive symptomatology in the elderly: data
487 from the Bordeaux sample of the Three-City Study. *Am J Clin Nutr* 2008;87:1156-
488 1162.
489 31. Samieri C, Feart C, Letenneur L, et al. Low plasma eicosapentaenoic acid and
490 depressive symptomatology are independent predictors of dementia risk. *Am J Clin*
491 *Nutr* 2008;88:714-721.
492 32. Wilk JB, Tsai MY, Hanson NQ, Gaziano JM, Djousse L. Plasma and dietary
493 omega-3 fatty acids, fish intake, and heart failure risk in the Physicians' Health Study.
494 *Am J Clin Nutr* 2012;96:882-888.
495 33. Kroger E, Verreault R, Carmichael PH, et al. Omega-3 fatty acids and risk of
496 dementia: the Canadian Study of Health and Aging. *Am J Clin Nutr* 2009;90:184-192.

497 34. Djousse L, Biggs ML, Lemaitre RN, et al. Plasma omega-3 fatty acids and
498 incident diabetes in older adults. *Am J Clin Nutr* 2011;94:527-533.
499 35. Merle BM, Delyfer MN, Korobelnik JF, et al. High concentrations of plasma n3
500 fatty acids are associated with decreased risk for late age-related macular
501 degeneration. *J Nutr* 2013;143:505-511.
502 36. Souied EH, Delcourt C, Querques G, et al. Oral Docosahexaenoic Acid in the
503 Prevention of Exudative Age-Related Macular Degeneration: The Nutritional AMD
504 Treatment 2 Study. *Ophthalmology* 2013;120:1619-1631.
505 37. Dole VP, Meinertz H. Microdetermination of long-chain fatty acids in plasma
506 and tissues. *J Biol Chem* 1960;235:2595-2599.
507 38. Benlian P, Cansier C, Hennache G, et al. Comparison of a new method for the
508 direct and simultaneous assessment of LDL- and HDL-cholesterol with
509 ultracentrifugation and established methods. *Clin Chem* 2000;46:493-505.
510 39. Leveziel N, Souied EH, Richard F, et al. PLEKHA1-LOC387715-HTRA1
511 polymorphisms and exudative age-related macular degeneration in the French
512 population. *Mol Vis* 2007;13:2153-2159.
513 40. Bonifacj C, Gerber M, Scali J, Daures JP. Comparison of dietary assessment
514 methods in a southern French population: use of weighed records, estimated-diet
515 records and a food-frequency questionnaire. *Eur J Clin Nutr* 1997;51:217-231.
516 41. Carriere I, Delcourt C, Lacroux A, Gerber M. Nutrient intake in an elderly
517 population in southern France (POLANUT): deficiency in some vitamins, minerals
518 and omega-3 PUFA. *Int J Vitam Nutr Res* 2007;77:57-65.
519 42. Favier J, Ireland-Ripert J, Toque C, Feinberg M. *Répertoire général des*
520 *aliments. Table de composition*. 2nde édition ed. Paris: Editions Tec et Doc Lavoisier
521 et INRA éditions; 1995.
522 43. Hercberg S. *Table de composition des aliments SU.VI.MAX*. Paris: Editions
523 INSERM; 2005.
524 44. Liu A, Chang J, Lin Y, Shen Z, Bernstein PS. Long-chain and very long-chain
525 polyunsaturated fatty acids in ocular aging and age-related macular degeneration. *J*
526 *Lipid Res* 2010;51:3217-3229.
527 45. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular
528 Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized
529 Clinical Trial. *JAMA* 2013;1-11.

530 46. Chew EY, Clemons TE, Agron E, et al. Long-Term Effects of Vitamins C and
531 E, beta-Carotene, and Zinc on Age-related Macular Degeneration: AREDS Report
532 No. 35. *Ophthalmology* 2013;120:1604-1611 e1604.
533 47. von Schacky C. The Omega-3 Index as a risk factor for cardiovascular
534 diseases. *Prostaglandins Other Lipid Mediat* 2011;96:94-98.
535 48. Rothman K, Greenland S. *Modern Epidemiology*. 2nd ed. Philadelphia:
536 Lippincott Williams & Wilkins; 1998.
537 49. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-
538 related macular degeneration: a systematic review and meta-analysis. *BMC*
539 *Ophthalmol* 2010;10:31.

Table 1: Characteristics of neovascular AMD patients and controls.

Characteristics	Controls n=144	Neovascular AMD patients n=290	Adjusted P*
Socio-demographic factors			
Age, y, mean ± SD	67.7±8.2	70.8±7.59	<0.0001
Gender, n (%)			0.69
Male	55 (38.2)	105 (36.2)	
Female	89 (61.8)	185 (63.8)	
Smoking status, n (%)			0.12
Never smoker	91 (63.2)	165 (56.9)	
Ever smoker	53 (36.8)	125 (43.1)	
BMI, kg/m^2, mean ± SD	25.2±3.7	25.7±3.97	0.17
Self-reported medical history			
Hypercholesterolemia, n (%)			0.0004
No	102 (70.8)	147 (51.4)	
Yes	42 (29.2)	143 (49.3)	
Hypertension, n (%)			0.001
No	102 (70.8)	149 (51.0)	
Yes	42 (29.2)	141 (48.6)	
Diabetes, n (%)			0.59
No	131 (91.0)	266 (91.7)	
Yes	13 (9.0)	24 (8.3)	
Family history of AMD, n (%)			0.004
No	125 (86.8)	222 (76.6)	
Yes	19 (13.2)	68 (23.5)	
Genetic polymorphisms			
CFH Y402H, n (%)			<0.0001
TT	56 (38.9)	63 (21.7)	
CT	68 (47.2)	134 (46.2)	
CC	20 (13.9)	93 (32.1)	
ARMS2 A69S, n (%)			<0.0001
GG	93 (64.6)	81 (27.9)	
GT	46 (31.9)	133 (45.9)	
TT	5 (3.5)	76 (26.2)	
ApoE, n (%)			
At least 1 allele E2	18 (12.5)	53 (18.3)	0.12
At least 1 allele E4	39 (27.1)	48 (16.6)	0.03
Plasma lipids, mmol/L, median (5th-95th percentiles) or mean ± SD			
Triglycerides	1.14 (0.57-2.30)	0.98 (0.48-2.17)	0.0009
HDL-Cholesterol	1.83±0.56	1.79±0.55	0.48
LDL-Cholesterol	3.91 (2.51-5.30)	3.64 (2.30-5.59)	0.29
Total Cholesterol	5.85±0.93	5.68±1.04	0.16
Circulating omega 3 PUFA, % of fatty acids, median (5th-95th percentiles)			
Serum EPA	0.74 (0.24-1.96)	0.60 (0.30-1.40)	0.03
Serum DHA	1.25 (0.63-2.00)	1.30 (0.60-2.40)	0.10
Serum EPA+DHA	1.99 (1.08-3.53)	1.90 (1.00-3.70)	0.78
Red Blood Cell Membranes EPA	0.78 (0.29-1.47)	0.60 (0.30-1.20)	<0.0001
Red Blood Cell Membranes DHA	3.51 (2.13-5.03)	3.20 (1.80-5.10)	0.03
Red Blood Cell Membranes EPA+DHA	4.32 (2.63-6.48)	3.80 (2.10-5.90)	0.001
Dietary intake of seafood, g/day, median (5th-95th percentiles)	N=139	N=284	
Total fish	19.9 (7.4-51.1)	17.1 (4.9-41.9)	0.05
Oily fish	8.2 (0.0-31.4)	5.5 (0.0-22.9)	0.02
White fish	9.9 (0.0-19.7)	9.9 (0.0-34.0)	0.68
Other seafood	1.8 (0.0-17.1)	0.7 (0.0-15.7)	0.16
Total seafood	22.7 (9.9-64.0)	20.4 (5.3-51.1)	0.03

AMD: age-related macular degeneration; BMI: body mass index; SD: standard deviation.

*p Student *t* test for age, Pearson Chi^2 for gender and logistic regression adjusted for age and gender for other variables.

Table 2: Variations of circulating n-3 PUFAs and dietary intake of fish according to socio-demographic factors, lifestyle and AMD-related genetic polymorphisms.

Characteristics	n	Serum EPA+DHA (% of fatty acids) Median (5^{th}-95^{th} percentiles)	RBCM EPA+DHA (% of fatty acids) Median (5^{th}-95^{th} percentiles)	n	Total fish (g/day) Median (5^{th}-95^{th} percentiles)	Oily fish (g/day) Median (5^{th}-95^{th} percentiles)	White fish (g/day) Median (5^{th}-95^{th} percentiles)
Socio-demographic factors							
Age, y							
<70	203	2.04 (1.15-3.70)	4.10 (2.47-5.83)	199	19.7 (5.3-51.1)	8.2 (0.0-31.4)	9.9 (2.5-19.7)
≥70	231	1.90 (0.90-3.60)	3.86 (2.11-6.02)	224	17.0 (4.9-42.6)	5.0 (0.0-22.9)	9.9 (0.0-38.4)
p*		0.11	0.20		0.05	0.0003	0.84
Gender							
Men	160	1.91 (1.05-3.70)	4.00 (2.45-5.86)	157	19.9 (4.9-58.3)	7.9 (0.0-31.4)	9.9 (0.0-39.4)
Women	274	1.91 (1.00-3.70)	4.00 (2.10-6.20)	266	15.7 (5.0-41.3)	5.4 (0.0-22.9)	9.9 (0.0-26.4)
p		0.61	0.71		0.002	0.005	0.25
Smoking status							
Never smoker	256	1.93 (1.11-3.70)	4.00 (2.20-6.40)	248	16.6 (5.0-42.6)	5.7 (0.0-21.4)	9.9 (2.5-24.1)
Ever smoker	178	1.91 (0.90-3.70)	4.00 (2.40-5.80)	175	19.7 (4.9-53.4)	7.9 (0.0-31.4)	9.9 (0.0-39.4)
p		0.32	0.72		0.06	0.17	0.31
BMI, kg/m²							
<25	218	2.00 (1.02-4.10)	4.05 (2.30-5.83)	211	19.7 (4.9-51.1)	5.7 (0.0-25.7)	9.9 (0.0-34.0)
≥25	214	1.90 (1.00-3.53)	4.00 (2.30-6.20)	212	17.8 (4.9-42.6)	7.5 (0.0-25.7)	9.9 (0.0-26.4)
p		0.30	0.61		0.71	0.67	0.31
Medical history							
Hypercholesterolemia							
No	245	1.90 (1.00-3.53)	4.03 (2.40-5.90)	237	18.4 (5.3-50.9)	7.9 (0.0-25.7)	9.9 (2.5-38.4)
Yes	189	2.00 (1.05-3.70)	4.00 (2.20-6.00)	186	21.0 (5.0-50.7)	5.5 (0.0-25.7)	19.0 (4.9-42.6)
p		0.95	0.62		0.44	0.31	0.70
Hypertension							
No	251	2.00 (1.00-3.60)	4.07 (2.40-6.20)	246	18.9 (5.3-45.4)	7.9 (0.0-25.7)	9.9 (0.0-34.0)
Yes	183	1.90 (1.05-3.70)	4.00 (2.20-5.90)	177	17.7 (4.9-47.2)	5.0 (0.0-22.9)	9.9 (0.0-26.9)
p		0.26	0.35		0.14	0.003	0.89
Diabetes							
No	397	2.00 (1.02-3.70)	4.03 (2.20-6.00)	386	18.9 (5.0-47.2)	7.5 (0.0-25.7)	9.9 (0.0-28.6)
Yes	37	1.60 (0.90-3.20)	3.50 (2.47-6.29)	37	15.7 (2.5-42.6)	5.4 (0.0-31.4)	9.9 (0.0-24.1)
p		0.05	0.09		0.47	0.90	0.40
Family history of AMD							
No	347	1.90 (1.02-3.60)	4.07 (2.39-5.90)	337	19.5 (4.9-45.4)	7.5 (0.0-25.7)	9.9 (0.0-34.0)
Yes	87	2.00 (1.00-3.90)	3.90 (2.20-6.20)	86	16.5 (7.1-47.3)	5.0 (0.0-25.7)	9.9 (2.5-23.3)
p		0.47	0.21		0.51	0.17	0.67
Genetic polymorphisms							
CFH Y402H							
CC	113	1.90 (1.10-4.00)	3.80 (2.20-6.29)	109	19.7 (4.9-42.6)	5.7 (0.0-25.7)	9.9 (2.5-34.0)
CT	202	1.96 (1.08-3.90)	4.10 (2.40-6.02)	198	19.7 (5.7-50.9)	7.9 (0.0-27.9)	9.9 (0.0-39.4)
TT	119	1.90 (0.90-3.00)	4.07 (2.10-5.70)	116	15.6 (3.6-48.3)	5.5 (0.0-22.9)	9.9 (0.0-19.7)
p		0.40	0.49		0.13	0.86	0.09
ARMS2 A69S							
GG	174	1.90 (1.02-3.90)	4.14 (2.50-6.02)	169	19.7 (4.9-51.1)	7.9 (0.0-31.4)	9.9 (0.0-34.0)
GT	179	2.00 (1.00-3.70)	4.03 (2.00-6.20)	176	17.9 (4.9-41.1)	5.7 (0.0-22.9)	9.9 (0.0-19.7)
TT	81	1.90 (1.20-3.10)	3.80 (2.60-5.62)	78	19.5 (5.0-58.0)	6.6 (0.0-31.4)	9.9 (0.0-39.4)
p		0.63	0.27		0.66	0.77	0.65
ApoE							
At least 1 E2 allele	71	1.90 (0.90-3.50)	3.75 (2.00-5.80)	69	19.9 (7.1-50.9)	7.9 (0.0-22.9)	9.9 (2.5-39.4)
No E2 allele	363	1.95 (1.10-3.70)	4.07 (2.40-6.00)	354	17.8 (4.9-45.1)	5.7 (0.0-25.7)	9.9 (0.0-26.4)
p		0.21	0.10		0.16	0.80	0.10
At least 1 E4 allele	87	1.90 (0.90-3.70)	4.10 (2.00-6.02)	84	19.8 (7.3-58.0)	7.9 (0.0-31.4)	9.9 (2.5-39.4)
No E4 allele	347	1.91 (1.10-3.70)	4.00 (2.30-6.00)	339	17.8 (4.9-42.6)	5.7 (0.0-25.7)	9.9 (0.0-24.1)
p		0.88	0.96		0.03	0.03	0.18

AMD: age-related macular degeneration; BMI: body mass index; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; n-3 PUFAs: omega 3 polyunsaturated fatty acids; RBCM: red-blood cell membranes.

* p for Wilcoxon test or Kruskal-Wallis ANOVA.

Table 3: Variations of circulating n-3 PUFAs according to dietary intake of seafood.

Dietary intake of seafood			SERUM (% of fatty acids) median (5^{th}-95^{th} percentiles)						RBCM (% of fatty acids) median (5^{th}-95^{th} percentiles)					
	Tertile	range (g/d)	EPA	p*	DHA	p	EPA+DHA	p	EPA	p	DHA	p	EPA+DHA	p
Total fish	1 n=151	[0 – 12.8]	0.60 (0.22-1.20)	<0.0001	1.20 (0.60-2.20)	0.0004	1.77 (0.90-3.10)	<0.0001	0.60 (0.29-1.00)	<0.0001	3.00 (1.70-5.10)	<0.0001	3.70 (1.90-5.70)	<0.0001
	2 n=147	]12.8 – 23.0[	0.70 (0.20-1.60)		1.30 (0.63-2.40)		2.00 (1.00-3.52)		0.60 (0.30-1.18)		3.22 (2.00-4.90)		3.92 (2.40-5.83)	
	3 n=125	[23.0 – 139.0]	0.76 (0.40-2.20)		1.40 (0.73-2.38)		2.20 (1.20-4.77)		0.80 (0.40-1.60)		3.70 (2.37-5.30)		4.50 (2.90-6.68)	
Oily fish	1 n=198	[0 – 5.4]	0.60 (0.23-1.34)	0.0008	1.20 (0.60-2.20)	0.02	1.80 (1.00-3.40)	0.002	0.60 (0.24-1.12)	<0.0001	3.00 (1.60-5.10)	0.0001	3.70 (2.00-5.77)	<0.0001
	2 n=125	]5.4 – 12.0[	0.75 (0.20-2.00)		1.30 (0.60-2.60)		2.00 (0.90-4.00)		0.79 (0.40-1.40)		3.40 (2.20-5.00)		4.29 (2.60-6.20)	
	3 n=100	[12.0 – 100.0]	0.70 (0.30-2.10)		1.37 (0.80-2.31)		2.20 (1.24-4.65)		0.71 (0.31-1.60)		3.71 (2.28-5.30)		4.55 (2.81-6.70)	
White fish	1 n=156	[0 – 9.0]	0.60 (0.22-1.23)	0.004	1.20 (0.60-2.10)	0.002	1.82 (0.90-3.10)	<0.0001	0.60 (0.30-1.10)	0.0002	3.20 (1.81-5.10)	0.08	3.86 (2.20-5.80)	0.01
	2 n=135	]9.0 – 14.0[	0.70 (0.24-1.70)		1.30 (0.70-2.40)		1.90 (1.00-3.70)		0.60 (0.29-1.20)		3.30 (1.90-4.80)		3.90 (2.20-5.80)	
	3 n=132	[14.0 – 69.0]	0.70 (0.25-2.15)		1.40 (0.70-2.38)		2.20 (1.10-4.00)		0.70 (0.40-1.60)		3.55 (1.80-5.30)		4.30 (2.39-6.40)	
Other seafood	1 n=254	[0 – 2.6]	0.60 (0.20-1.40)	0.05	1.27 (0.63-2.20)	0.01	1.90 (1.0-3.41)	0.002	0.60 (2.29-1.16)	0.008	3.20 (1.80-5.32)	0.03	3.80 (2.10-6.29)	0.003
	2 n=86	]2.6 – 7.0[	0.67 (0.29-1.82)		1.23 (0.60-2.30)		1.90 (1.00-4.13)		0.61 (0.33-1.40)		3.32 (2.00-4.96)		4.10 (2.60-5.70)	
	3 n=83	[7.0 – 62.9]	0.73 (0.30-2.00)		1.40 (0.80-2.40)		2.20 (1.20-4.00)		0.70 (0.33-1.56)		3.67 (2.20-4.90)		4.50 (2.60-5.80)	
Total seafood	1 n=142	[0 – 15.7]	0.60 (0.25-1.10)	<0.0001	1.17 (0.60-2.20)	<0.0001	1.70 (1.00-3.10)	<0.0001	0.57 (0.28-0.98)	<0.001	3.00 (1.80-5.10)	0.001	3.65 (2.10-5.70)	<0.0001
	2 n=142	]15.7 – 26.0[	0.60 (0.18-1.42)		1.29 (0.60-2.10)		1.90 (0.90-3.41)		0.60 (0.30-1.12)		3.29 (1.80-4.94)		3.91 (2.30-5.83)	
	3 n=139	[26.0 - 155.4]	0.80 (0.40-2.20)		1.40 (0.71-2.40)		2.26 (1.20-4.40)		0.80 (0.40-1.60)		3.70 (2.20-5.10)		4.50 (2.60-6.40)	

EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; n-3 PUFAs: omega 3 polyunsaturated fatty acids; RBCM: red-blood cell membranes. n=423.
* p for Kruskal-Wallis ANOVA.

Table 4: Associations of dietary intake of seafood with neovascular AMD.

Dietary intake of seafood			Model 1*			Model 2†		
	Tertile	range (g/d)	OR	(95 % CI)	P for trend	OR	(95 % CI)	P for trend
Total fish	1	[0 – 12.8]	1.00	ref	0.04	1.00	ref	0.21
	2	]12.8 – 23.0[	0.63	(0.38-1.05)		0.55	(0.30-1.00)	
	3	[23.0 – 139.0]	0.57	(0.34-0.97)		0.69	(0.37-1.29)	
Oily fish	1	[0 – 5.4]	1.00	ref	0.13	1.00	ref	0.56
	2	]5.4 – 12.0[	0.85	(0.52-1.39)		0.99	(0.55-1.80)	
	3	[12.0 – 100.0]	0.67	(0.40-1.12)		0.82	(0.44-1.53)	
White fish	1	[0 – 9.0]	1.00	ref	0.34	1.00	ref	0.17
	2	]9.0 – 14.0[	1.00	(0.60-1.67)		1.25	(0.68-2.29)	
	3	[14.0 – 69.0]	0.79	(0.47-1.29)		0.63	(0.34-1.15)	
Other seafood	1	[0 – 2.6]	1.00	ref	0.10	1.00	ref	0.64
	2	]2.6 – 7.0[	0.60	(0.36-1.01)		0.59	(0.32-1.11)	
	3	[7.0 – 62.9]	0.71	(0.42-1.20)		0.98	(0.52-1.86)	
Total seafood	1	[0 – 15.7]	1.00	ref	0.05	1.00	ref	0.22
	2	]15.7 – 26.0[	0.60	(0.36-1.01)		0.50	(0.27-0.92)	
	3	[26.0 - 155.4]	0.59	(0.35-0.99)		0.68	(0.36-1.28)	

AMD: age-related macular degeneration.

* Model 1: OR estimated using logistic regression adjusted for age and gender. AMD patients n=284, Controls n=139.

† Model 2: OR estimated using logistic regression adjusted for age, gender, *CFH Y402H*, *ARMS2 A69S*, and *ApoE4* polymorphisms, plasma triglycerides, hypertension, hypercholesterolemia and family history of AMD. AMD patients n=284, Controls n=139.

Table 5: Associations of circulating n-3 PUFAs with neovascular AMD.

			Model 1*			Model 2†		
	Tertile	range (% of fatty acids)	OR	(95 % CI)	P for trend	OR	(95 % CI)	P for trend
Serum								
EPA	1	[0 – 0.5]	1.00	ref	0.04	1.00	ref	0.005
	2	]0.5 – 0.9[	0.61	(0.37-1.00)		0.50	(0.27-0.91)	
	3	[0.9 - 3.7]	0.59	(0.36-0.98)		0.41	(0.22-0.77)	
DHA	1	[0 – 1.1]	1.00	ref	0.46	1.00	ref	0.81
	2	]1.1 – 1.5[	0.66	(0.40-1.07)		0.69	(0.39-1.24)	
	3	[1.5 - 3.9]	1.23	(0.74-2.04)		1.10	(0.60-2.01)	
EPA+DHA	1	[0 – 1.7]	1.00	ref	0.87	1.00	ref	0.35
	2	]1.7 – 2.4[	1.10	(0.67-1.80)		0.95	(0.53-1.72)	
	3	[2.4 - 7.5]	0.96	(0.58-1.59)		0.74	(0.40-1.38)	
RBCM								
EPA	1	[0 – 0.5]	1.00	ref	<0.0001	1.00	ref	<0.0001
	2	]0.5 – 0.8[	0.63	(0.37-1.09)		0.46	(0.24-0.87)	
	3	[0.8 - 3.4]	0.33	(0.20-0.55)		0.25	(0.13-0.47)	
DHA	1	[0 – 2.9]	1.00	ref	0.09	1.00	ref	0.37
	2	]2.9 – 3.9[	0.51	(0.31-0.83)		0.59	(0.33-1.07)	
	3	[3.9 - 7.3]	0.64	(0.38-1.07)		0.76	(0.41-1.39)	
EPA+DHA	1	[0 – 3.5]	1.00	ref	0.002	1.00	ref	0.03
	2	]3.5 – 4.6[	0.53	(0.32-0.89)		0.60	(0.33-1.10)	
	3	[4.6 - 9.3]	0.44	(0.27-0.74)		0.52	(0.29-0.94)	

AMD: age-related macular degeneration; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; n-3 PUFAs: omega 3 polyunsaturated fatty acids; RBCM: red-blood cell membranes.

* Model 1: OR estimated using logistic regression adjusted for age and gender. AMD patients n=290, Controls n=144.

† Model 2: OR estimated using logistic regression adjusted for age, gender, *CFH Y402H*, *ARMS2 A69S*, and *ApoE4* polymorphisms, plasma triglycerides, hypertension, hypercholesterolemia and family history of AMD. AMD patients n=290, Controls n=144.